Documentos de Académico
Documentos de Profesional
Documentos de Cultura
CLASE 8.0
Dosificación centrada en el paciente
Dr. Carlos Herrera Ugarte
“sweet spot”
Step by step
Epidiolex
Sativex
Farmacodinamia, es el estudio de los efectos bioquímicos y
fisiológicos de los fármacos y de sus mecanismos de acción y la
relación entre la concentración del fármaco y el efecto de este
sobre un organismo.
- Cromosoma 7
- Sweet spot
- Referencias en línea.
Cómo conservar el medicamento y
cuál es la vida de anaquel.
Métodos de análisis del
sistema endocannabinoide:
NAPE: N-acylphospathidyl
ethanolamine
Sativex
Epidiolex
Bibliografía:
Russo, E. B. (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable
Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165. doi:10.1089/can.2016.0009
Cogan, P. S. (2020). Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endo-
cannabinoid Deficiency. Journal of Dietary Supplements, 1–17. doi:10.1080/19390211.2020.1769246
Werk, A. N., & Cascorbi, I. (2014). Functional Gene Variants of CYP3A4. Clinical Pharmacology & Therapeutics, 96(3), 340–348. doi:10.1038/-
clpt.2014.129
Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Arthur, M., Fleming, S., … Riedel, G. (2011). Plasma and brain pharmacokinetic profile of cannabi-
diol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal
administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology, 219(3), 859–873. doi:10.1007/s00213-011-2415-0
Vermersch, P. (2011). Sativex®(tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Expert Review of Neurotherapeutics, 11(sup4), 15–19. doi:10.1586/ern.11.27
Zelber-Sagi, S., Azar, S., Nemirovski, A., Webb, M., Halpern, Z., Shibolet, O., & Tam, J. (2016). Serum levels of endocannabinoids are independently
associated with nonalcoholic fatty liver disease. Obesity, 25(1), 94–101. doi:10.1002/oby.21687
Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020). Endocannabinoid
System Components as Potential Biomarkers in Psychiatry. Frontiers in Psychiatry, 11. doi:10.3389/fpsyt.2020.00315
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., … Abdelalim, A. (2018). Global, regional, and national incidence, prevalence,
and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden
of Disease Study 2017. The Lancet, 392(10159), 1789–1858. doi:10.1016/s0140-6736(18)32279-7
Di Marzo, V., & Piscitelli, F. (2015). The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics, 12(4), 692–698.
doi:10.1007/s13311-015-0374-6
Minichino, A., Senior, M., Brondino, N., Zhang, S. H., Godwlewska, B. R., Burnet, P. W. ., … Lennox, B. R. (2019). Measuring Disturbance of the Endocan-
nabinoid System in Psychosis. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2019.0970
Buczynski, M. W., & Parsons, L. H. (2010). Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. British Journal of
Pharmacology, 160(3), 423–442. doi:10.1111/j.1476-5381.2010.00787.x
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2018). Cannabidiol presents an inverted
U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry. doi:10.1590/1516-4446-2017-0015
Giacoppo, S., Bramanti, P., & Mazzon, E. (2017). Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade
of clinical evaluation. Multiple Sclerosis and Related Disorders, 17, 22–31. doi:10.1016/j.msard.2017.06.015
Special thanks to Alexandra Elbakyan.